Cerebral oligemic hypoxia and MK-801 treatment: Effect on alternation behavior in mice

Pharmacological Reports

Volumn 58, Issue 5, 2006, Pages 770-773

  Jóźwiak, Lucyna ^a   Łukawski, Krzysztof ^a   Sieklucka Dziuba, Maria ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Cerebral oligemic hypoxia; Mice; ML 801; Spontaneous alternation

Indexed keywords

DIZOCILPINE; PENTOBARBITAL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY CLAMP; ARTICLE; BEHAVIOR DISORDER; BRAIN BLOOD FLOW; BRAIN HYPOXIA; CAROTID ARTERY FLOW; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; LOCOMOTION; MALE; MAZE TEST; MOUSE; MOUSE STRAIN; NONHUMAN; TASK PERFORMANCE;

EID: 33750984792     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Akunne HC, Reid AA, Thurkauf A, Jacobson AE, de Costa BF, Rice KC, Heyes MP, Rothman RB: [3H] 1-[2(2-thienyl)cyclohexyl]piperidine labels two high-affinity binding sites in human cortex: further evidence for phencyclidine binding sites associated with the biogenic amine reuptake complex. Synapse, 1991, 8, 289-300.
2. Bischoff C, Tiedtke PI: Competitive and non-competitive NMDA receptor antagonists in spatial learning tasks. Eur J Pharmacol, 1992, 213, 269-273.
3. Clineschmidt BV, Martin GE, Bunting PR: Anticonvulsant activity of (+)-5-methyl-10, 11-dihydro-5H-dibenzo [a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic and apparent anxiolytic properties. Drug Dev Res, 1982, 2, 123-134.
4. Danysz W, Essmann U, Bresink I, Wilke R: Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav, 1994, 48, 111-118.
5. Danysz W, Wróblewski JT, Costa E: Learning impairment in rats by N-methyl-D-aspartate receptor antagonists. Neuropharmacology, 1988, 27, 653-656.
6. French ED, Mura A, Wang T: MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists. Synapse, 1993, 13, 108-116.
7. Ginsberg MD, Takagi K, Globus MY-T: Release of neurotransmitters in cerebral ischemia: relevance to neuronal injury. In: Pharmacology of Cerebral Ischemia. Ed. Krieglstein J, Oberpichler-Schwenk H, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1992, 177-190.
8. Heim C, Sieklucka M, Block F, Schmidt-Kastner R, Jaspers R, Sontag K-H: Transient occlusion of carotid arteries leads to disturbed spatial learning and memory in the rat. In: Pharmacology of Cerebral Ischemia. Ed. Krieglstein J, Oberpichler H, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1990, 53-61.
9. Heim C, Zhang J, Lan J, Sicklucka M, Kurz T, Riederer P, Gerlach M, Sontag K-H: Cerebral oligaemia episode triggers free radical formation and late cognitive deficiencies. Eur J Neurosci, 2000, 12, 715-725.
10. Irifune M, Shimizu T, Nomoto M, Fukuda T: Involvement of N-methyl-D-aspartate (NMDA) receptors in noncompetitive NMDA receptor antagonist induced hyperlocomotion in mice. Pharmacol Biochem Behav, 1995, 51, 291-296.
11. Jóźwiak L, Łukawski K, Czuczwar SJ, Sieklucka-Dziuba M: Competitive NMDA receptor antagonists and agonist: effects on spontaneous alternation in mice exposed to cerebral oligemia. Pol J Pharmacol, 2004, 56, 59-66.
12. Nehls DG, Kurumaji A, Park CK, Mc Culloch J: Differential effect of competitive and non-competitive N-methyl-D-aspartate antagonists on glucose use in the limbic system. Neurosci Lett, 1988, 91, 204-210.
13. Nishimura M, Sato K, Okada T, Schloss P, Shimada S, Tohyama M: MK-801 blocks monoamine transporters expressed in HEK cells. FEBS Lett, 1998, 423, 376-380.
14. Parada-Turska J, Turski WA: Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-D-aspartate receptors in learning and memory tasks. Neuropharmacology, 1990, 29, 1111-1116.
15. Reid AA, Mattson MV, de Costa BR, Thurkauf A, Jacobson AE, Monn JA, Rice KC, Rothman RB: Specificity of phencyclidine-like drugs and benzomorphan opiates for two high affinity phencyclidine binding sites in guinea pig brain. Neuropharmacology, 1990, 29, 811-817.
16. Sarter M, Bodewitz G, Stephens DN: Attenuation of scopolamine-induced impairment of spontaneous alternation behavior by antagonist but not inverse agonist and agonist β-carbolines. Psychopharmacology, 1988, 94, 491-495.
17. Sieklucka M, Heim C, Block F, Sontag K-H: Transient reduction of cerebral blood flow leads to long-lasting increase in GABA content in vulnerable structures and decreased susceptibility to bicuculline induced seizures. J Neural Transm, 1992, 88, 87-94.
18. Snell LD, Yi S-J, Johnson KM: Comparison of the effects of MK-801 and phencyclidine on catecholamine uptake and NMDA-induced norepinephrine release. Eur J Pharmacol, 1988, 145, 223-226.
19. Sontag K-H, Heim C, Block F, Sieklucka M, Schmidt-Kastner R, Melzacka M, Osborne N et al: Cerebral oligemic hypoxia and forebrain ischemia - common and different long-lasting consequences. In: Pharmacology of Cerebral Ischemia. Ed. Kriegistein J, Oberpichler-Schwenk H, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1992, 471-479.
20. Troupin AS, Mendius JR, Cheng F, Risinger MW: MK-801. In: New Anticonvulsant Drugs. Ed. Meldrum BS, Porter RJ, John Libbey, London, 1986, 191-201.
21. Wozniak DF, Brosnan-Watters G, Nardi A, Mc Ewen M, Corso TD, Olney JW, Fix AS: MK-801 neurotoxicity in male mice: histological effects and chronic impairment in spatial learning. Brain Res, 1996, 707, 165-179.